Intrahepatic Cholestasis of Pregnancy
Clinical Snapshot
Intrahepatic cholestasis of pregnancy (ICP) is the most common hepatic disease unique to pregnancy, with an incidence that varies enormously by geography and ethnicity — roughly 0.1-0.3% in North America, compared with 1.5-3.2% in northern Europe, 4-6.5% in Chile, and over 27% in the Mapuche, an Indigenous Chilean population.[1] The condition is defined by the combination of maternal pruritus — most classically of the palms and soles — together with an elevation in non-fasting total serum bile acids (TSBA), typically presenting in the late second or early third trimester.[1]
ICP itself is not associated with serious maternal complications, but its fetal sequelae are genuinely significant: spontaneous and iatrogenic preterm birth, meconium-stained amniotic fluid, neonatal respiratory distress, neonatal intensive care unit (NICU) admission, and stillbirth.[1] What sets this chapter apart from most others in this library is that a single laboratory value — the highest non-fasting bile acid level recorded at any point in the pregnancy — is what actually drives the delivery-timing decision, more than gestational age or symptom severity on their own.[1] For a community or prenatal pharmacist, this is genuinely high-yield territory: ursodeoxycholic acid (UDCA) is the mainstay pharmacologic treatment, and the counselling points around its real (symptom relief, modestly lower preterm birth risk) versus overstated (stillbirth prevention) benefits, correct dosing and titration, and distinguishing ICP from other causes of pregnancy pruritus are all squarely pharmacist territory.
Recognize the Condition
A hormonal, genetic, and environmental disease
The etiology of ICP is genuinely multifactorial — a combination of hormonal factors, an underlying genetic predisposition, and environmental influences that only manifest as clinical disease during pregnancy.[1]
What drives ICP
Three overlapping contributors, not a single cause.
Hormonal factors
Rising estrogen and progesterone metabolites late in pregnancy are believed to alter the expression of hepatic bile-acid transport proteins and receptors. Oral progesterone supplementation in early pregnancy has itself been associated with an increased risk of ICP.
Genetic susceptibility
Heterozygous variants in several genes involved in bile-acid synthesis and transport increase risk, particularly genes associated with the autosomal recessive disorder progressive familial intrahepatic cholestasis — ABCB4, ABCB11, and ATP8B1 — along with altered genes such as NR1H4 (farnesoid X receptor), ABCC2, and NR1I2 (pregnane X receptor). ABCB4 encodes a hepatocyte transporter responsible for exporting phosphatidylcholine into bile; when impaired, bile becomes more toxic to the biliary epithelium and cholestasis results.
Environmental influences
Selenium or vitamin D deficiency, winter conception or pregnancy, multiparity, multiple gestation, diabetes mellitus, hepatitis C, a personal or family history of ICP, advanced maternal age, and assisted reproductive technology.
Pathophysiology — a reversed maternal-fetal bile acid gradient
Bile acids are produced and cleared by the liver in a tightly regulated manner, given their cytotoxic potential. In a healthy pregnancy, a favourable gradient runs from the fetal to the maternal compartment, clearing bile acids away from the fetus and protecting it from their toxic effects; fetal bile acid production itself begins as early as 12 weeks' gestation. In ICP, a significant rise in maternal bile acids reverses this gradient, so bile acids instead accumulate within the fetal compartment — the mechanistic basis for the condition's fetal risk.[1]
Clinical presentation
The cardinal symptom is pruritus, most classically affecting the palms of the hands and soles of the feet and often reported as worse at night. Itching usually begins in the latter half of the second trimester or early in the third, and can precede any abnormal laboratory finding by 3-4 weeks — a normal bile acid level at first presentation does not rule out the diagnosis and should prompt repeat testing, not reassurance (see Assessment & Diagnosis).[1]
There is no primary dermatologic lesion in ICP — this is one of the most clinically important distinguishing features from other pregnancy-specific dermatoses, such as polymorphic eruption of pregnancy or pemphigoid gestationis, both of which do produce a primary rash. Any skin findings in ICP are secondary to scratching — excoriations and prurigo nodules — not a primary eruption; a genuine primary rash should prompt reconsideration of the diagnosis.[1] Jaundice is present in 10-15% of patients, with onset roughly 3 weeks after pruritus begins; encephalopathy or other signs of fulminant liver failure are rare and warrant urgent specialist evaluation rather than routine ICP management. Other reported but atypical symptoms include nausea, fatigue, abdominal pain, pale stool or steatorrhea, dark urine, and malaise — systemic complaints like these are atypical for ICP and should prompt evaluation for an alternative or additional diagnosis rather than default attribution to ICP.[1]
Risk Factors
- Personal or family history of ICP — the single strongest predictor; recurrence in a future pregnancy is 70-90% (see Special Populations).
- Multiple gestation (twin or higher-order pregnancy).
- Multiparity.
- Advanced maternal age.
- Assisted reproductive technology, including conception after in vitro fertilization.
- Pre-existing hepatitis C infection or other underlying liver disease.
- Diabetes mellitus.
- Selenium or vitamin D deficiency.
- Winter-season conception or pregnancy.
- Ethnicity — higher incidence reported in Latino, South Asian, and Chilean (particularly Mapuche) populations.
- A known pathogenic variant in a bile-acid transport gene (ABCB4, ABCB11, ATP8B1), or a personal/family history of another hepatobiliary condition linked to these genes (e.g., non-pregnancy cholestasis, gallstones).
- Oral progesterone supplementation started in early pregnancy.
Red Flags & Refer
Escalate promptly for any of the following:
- Bile acids ≥100 µmol/L at any point — this is the threshold at which stillbirth risk rises sharply (adjusted odds ratio 30.50 versus bile acids under 40 µmol/L) and both fetal monitoring intensity and delivery timing change substantially (see Choose Initial Treatment).[2]
- Jaundice, encephalopathy, or any other sign suggestive of fulminant or severe hepatic dysfunction — not typical of uncomplicated ICP; refer urgently to hepatology, internal medicine, or maternal-fetal medicine.[1]
- Onset of pruritus before the late second trimester, a primary dermatologic eruption (not simply excoriations), an abnormal bilirubin or gamma-glutamyl transferase (GGT), or other atypical systemic symptoms — reconsider the diagnosis and broaden the workup rather than defaulting to ICP.[1]
- Clinical signs of coagulopathy — easy bruising, petechiae, severe epistaxis, gingival bleeding, hematuria, or hemarthrosis — evaluate for vitamin K deficiency, which in ICP is generally associated with severe steatorrhea from fat-soluble vitamin malabsorption in prolonged, severe disease.[1]
- Reduced fetal movement at any point — this needs immediate assessment regardless of the current bile acid level or gestational age. Fetal movement monitoring is the mainstay of fetal wellbeing surveillance in ICP precisely because electronic fetal heart rate monitoring and ultrasound have not been shown to reliably predict which fetus will decompensate.[1]
- Rapidly rising bile acids on serial testing, particularly approaching or crossing the 100 µmol/L threshold — this changes both monitoring intensity and the delivery-timing plan (see Choose Initial Treatment).[1]
Assessment & Diagnosis
Diagnostic criteria
ICP is a diagnosis of exclusion, confirmed once a pregnant patient with pruritus — particularly of the palms and soles, in the late second or third trimester — has an elevation in total serum bile acids (TSBA), with or without an accompanying rise in liver transaminases. The contemporary, evidence-based diagnostic threshold is a non-fasting bile acid level greater than 19 µmol/L. Non-fasting sampling matters: bile acids rise physiologically after eating, and a fasting or non-pregnant reference range risks missing mild disease — in one study, patients with mild ICP had fasting bile acid levels as low as 10 µmol/L, within the normal non-pregnant range.[1]
Liver transaminases (ALT/AST) are often elevated in ICP and may even precede the rise in bile acids, but a meta-analysis found no correlation between the degree of transaminase elevation and perinatal outcomes — transaminases cannot be used to establish the diagnosis or to predict stillbirth risk on their own. Because ICP is cholestatic, gamma-glutamyl transferase (GGT) and bilirubin are typically normal; a significantly elevated GGT or bilirubin is atypical for ICP and should prompt investigation for an alternative diagnosis rather than being folded into the ICP picture.[1]
When to test, and how often
In a pregnant patient with pruritus, a reasonable clinical suspicion of ICP, and a non-fasting bile acid level of 19 µmol/L or under, repeat testing every 2-4 weeks — pruritus can precede an abnormal bile acid level by 3-4 weeks, so a single normal result at first presentation does not exclude the diagnosis.[1]
Ruling out alternative and coexisting diagnoses
ICP shares some management principles with, but is a genuinely distinct disease process from, preeclampsia and HELLP syndrome — those conditions usually involve multisystem or fetoplacental hepatic dysfunction, whereas ICP specifically and disproportionately targets the liver; the two disease processes can also coexist in the same pregnancy.[1] Reconsider the diagnosis, and broaden the workup, whenever any atypical feature is present: symptom onset before the late second trimester, a primary dermatologic eruption rather than only secondary excoriations, jaundice, or a significantly abnormal bilirubin or GGT.[1] Routine testing for viral infections (Epstein-Barr virus, cytomegalovirus, hepatitis A/B/C) and autoimmune markers (antinuclear, anti-smooth-muscle, and anti-mitochondrial antibodies) has a low diagnostic yield in an otherwise typical presentation and is not routinely recommended — reserve it for atypical presentations; hepatitis B is already routinely screened for in the first trimester as part of standard prenatal care. Abdominal imaging has no pathognomonic finding in ICP and should likewise be reserved for select cases, not performed routinely.[1]
Vitamin K / coagulopathy testing
Routine testing for vitamin K deficiency or coagulopathy (prothrombin time [PT], partial thromboplastin time [PTT], INR) is not recommended in typical ICP. Reserve this testing for patients with clinical evidence of a bleeding tendency (see Red Flags & Refer) — clinically significant vitamin K deficiency in ICP is rare, and when it occurs is generally linked to severe steatorrhea from fat-soluble vitamin malabsorption, or to an adverse reaction to a bile-acid sequestrant such as cholestyramine, which is not used in contemporary practice for this condition.[1]
Bile-acid-based stillbirth risk stratification
The single most clinically important number in ICP is the highest recorded non-fasting bile acid level in the current pregnancy — it drives both fetal monitoring intensity and delivery timing (see Choose Initial Treatment). A large individual-participant-data meta-analysis (5,269 ICP pregnancies versus 165,136 controls, across 15 countries) established the following relationship between the highest bile acid level and stillbirth risk:[2]
| Highest non-fasting bile acid level | Stillbirth risk | Comparison to baseline |
|---|---|---|
| Under 40 µmol/L | 0.12% (3 of 2,310 cases) | Equivalent to the general obstetric population. |
| 40-99 µmol/L | 0.28% (4 of 1,412 cases) | Equivalent to population data overall; risk may increase from 38 weeks onward, though the number of cases studied at later gestational ages is limited. |
| 100 µmol/L or higher | 3.44% overall (range 3-44% across included studies) | Adjusted odds ratio 30.50 (95% CI 8.83-105.30) versus bile acids under 40 µmol/L — a substantial, clinically actionable increase. |
Within the contemporary Canadian context, the baseline population stillbirth rate is approximately 0.28% — closely matching the risk seen with bile acids under 100 µmol/L, which reinforces that it is specifically the 100 µmol/L-and-above category that carries meaningfully elevated risk.[1]
Maternal comorbidities associated with ICP
Patients diagnosed with ICP have an increased risk of both preeclampsia (pooled odds ratio 2.58, 95% CI 2.37-2.81) — typically diagnosed 2-4 weeks after the ICP diagnosis — and gestational diabetes mellitus (pooled odds ratio 2.19, 95% CI 1.58-3.03). Screen and monitor for both rather than treating ICP as an isolated diagnosis.[1]
Treatment Targets
- Relieve maternal pruritus to a tolerable level.
- Reduce the risk of stillbirth, iatrogenic and spontaneous preterm birth, meconium-stained amniotic fluid, neonatal respiratory distress, and NICU admission — recognizing that available pharmacologic treatment reliably achieves the first goal but has not been proven to achieve most of the second.
- Correctly stratify fetal risk using the highest recorded non-fasting bile acid level, and use that stratification to guide monitoring intensity and delivery timing.
- Avoid ineffective treatments, so genuinely effective interventions — accurate testing and correctly timed delivery — are not delayed or substituted for by a false sense of having already "treated" the fetal risk.
- Identify and manage the maternal comorbidities (preeclampsia, gestational diabetes) that occur at meaningfully increased rates alongside ICP.
- Counsel every patient on the expected postpartum course, the high recurrence risk in future pregnancies, and relevant long-term hepatobiliary and metabolic follow-up.
Choose Initial Treatment
Every treatment and monitoring decision in ICP is anchored to a single number: the highest non-fasting total serum bile acid (TSBA) level recorded at any point in the current pregnancy — not the most recent value, and not an average. A falling level on treatment does not reset the risk category. Broadly: mild 20-39 µmol/L, moderate 40-99 µmol/L, severe 100 µmol/L or higher.[1][2]
1st line, all severities topical emollients and an oral antihistamine such as hydroxyzine are safe in pregnancy and may be offered for pruritus relief. Neither has been specifically evaluated for efficacy in ICP, and neither lowers bile acid levels or improves fetal outcomes — treat them as comfort measures, not disease-modifying therapy.[1]
Recommended — severe ICP (bile acids ≥100 µmol/L) ursodeoxycholic acid, unless delivery is otherwise indicated. UDCA is itself a bile acid and alters bile-salt composition, replacing roughly 60% of more harmful (hydrophobic) bile salts; it has a reassuring overall safety profile, with gastrointestinal upset as the most common adverse effect.[1]
Dose: 10-15 mg/kg/day PO in 2-3 divided doses; a typical starting dose is 500 mg PO every 12 hours. If pruritus is not relieved to a tolerable level within 2 weeks, the dose may be titrated every 1-2 weeks as needed, to a maximum of 20 mg/kg/day.[1]
Consider, shared decision-making — non-severe ICP (bile acids under 100 µmol/L) UDCA may be offered for symptom relief. A meta-analysis of UDCA versus placebo or other treatments found a modest improvement in maternal pruritus (mean difference -7.64 points on a 100-point visual analog scale, 95% CI -9.69 to -5.60), and a separate individual-participant-data meta-analysis found UDCA reduced the risk of preterm birth, with a number needed to treat of 15 — genuine, if modest, benefits, even without a demonstrated mortality benefit.[1]
What UDCA has not been shown to do: the PITCHES trial — a double-blind, placebo-controlled randomized trial of UDCA 500 mg twice daily from 20-40 weeks' gestation in 605 patients — found no difference in the composite endpoint of perinatal death, preterm delivery, or NICU admission, and no reduction in total bile acid levels compared with placebo. A prespecified subgroup with severely elevated bile acids (over 100 µmol/L) also showed no difference, though this subgroup was small (23 treatment, 17 placebo patients). A 2020 Cochrane review similarly could not draw definitive conclusions about a benefit for fetal compromise or stillbirth.[3][1] Counsel patients accurately: UDCA is genuinely useful for symptom relief and may modestly lower preterm birth risk, but it is not a proven way to prevent stillbirth — correctly timed delivery remains the actual risk-reduction strategy for severe disease (see Step 6).
For patients whose pruritus or bile acid levels do not improve on UDCA, refer to a specialist (hepatologist, obstetric internist, or maternal-fetal medicine) to evaluate for an underlying medical or genetic predisposition. Addition of rifampin (rifampicin) to UDCA may be considered in this setting — dose range 300-1200 mg/day — a case series of 28 patients with severe, refractory ICP showed a reduction in bile acid levels with the addition of rifampin to UDCA. Initiation should be discussed with, and generally directed by, a specialist rather than started independently, given rifampin's extensive drug-interaction profile.[1]
The following have specifically been studied for ICP and shown to be ineffective; do not prescribe them to treat the condition: dexamethasone, cholestyramine, phenobarbital, S-adenosylmethionine, activated charcoal, and epomediol.[1]
Only with demonstrated deficiency/coagulopathy maternal vitamin K supplementation (10 mg PO once daily) is indicated only in patients with a demonstrated vitamin K deficiency and/or coagulopathy with an abnormal PT — not routinely. See Assessment & Diagnosis for testing indications.[1]
Base the delivery-timing decision on the highest non-fasting bile acid level recorded at any point in the pregnancy — not the level at the time delivery is being planned. A patient whose bile acids have since fallen on treatment is still risk-stratified by their peak value.[1]
| Highest bile acid level | Recommended delivery timing |
|---|---|
| 20-39 µmol/L | 39+0 to 39+6 weeks. |
| 40-69 µmol/L | 38+0 to 38+6 weeks. |
| 70-99 µmol/L | 36+0 to 37+6 weeks. |
| 100 µmol/L or higher | By 36 weeks' gestation, or earlier in patients with additional comorbidities or risk factors — multiple gestation, preeclampsia, gestational diabetes, a previous stillbirth secondary to ICP, and/or severe persistent maternal pruritus. |
These bands are based on expert opinion rather than high-quality trial evidence — individualize the final decision through shared decision-making, incorporating comorbidities and patient preference. Give antenatal corticosteroids per standard gestational-age-based recommendations if the risk of delivery within the next 7 days is high. ICP itself does not increase the likelihood of needing an assisted vaginal birth or cesarean delivery — base the mode of delivery on standard obstetric and medical indications.[1]
Offer continuous electronic fetal heart rate monitoring in labour, given the increased incidence of adverse outcomes in ICP; repeat bile acid testing is not typically performed intrapartum.[1]
Non-Pharmacologic Treatment
- Advise every patient to monitor fetal movements daily as the mainstay of fetal wellbeing surveillance in ICP, and to seek prompt assessment for any reduction — this remains recommended even though it has not been formally validated for ICP specifically, given the absence of a better alternative.[1]
- Electronic fetal heart rate monitoring (cardiotocography) and ultrasound surveillance, alone or combined, have not been shown to accurately identify which fetuses are at increased risk of stillbirth or other adverse outcomes in ICP — a reassuring antenatal test does not rule out subsequent fetal compromise, and this should be communicated clearly to any patient offered it.[1]
- Additional fetal monitoring beyond movement counting is not mandated, but individual units may reasonably offer it after discussion and shared decision-making, based on local resources and the patient's risk category (see Monitoring & Follow-Up for one example protocol tied to bile acid level).[1]
- Routine third-trimester growth ultrasound is not specifically required because of an ICP diagnosis — fetal growth restriction has not been shown to be increased in ICP, and isolated ICP does not raise the likelihood of placental insufficiency. Where a centre does not otherwise perform routine third-trimester growth ultrasound, one may still reasonably be offered to rule out growth restriction and confirm no other risk factors are present.[1]
- There is no evidence-based recommendation for a specific analgesic or anesthetic approach in labour, or for altered management of the third stage, specific to ICP.[1]
- Cool compresses, loose-fitting clothing, and lukewarm (not hot) bathing are reasonable general comfort measures for pruritus, though none has been specifically studied in ICP.
Special Populations
Multiple gestation
Twin and higher-order pregnancies are both a risk factor for developing ICP and, when ICP is present, an independent factor favouring earlier delivery within the relevant bile-acid-based timing band (see Choose Initial Treatment).[1]
Breastfeeding
Ursodeoxycholic acid and hydroxyzine are both considered compatible with breastfeeding; confirm specifics against each drug's own Drug Database entry.
Family members and genetic testing
If ICP develops before 32 weeks' gestation, there is roughly a 20% chance the patient carries a pathogenic variant in ABCB11 or ABCB4. In this situation, referral to a specialist in clinical genetics, internal medicine, or maternal-fetal medicine is recommended for consideration of genetic testing — both for the patient's own future risk and because female first-degree relatives, particularly siblings, share this risk.[1]
Postpartum course and follow-up
Both symptoms and ICP-associated biochemical abnormalities are expected to resolve within 1-2 weeks postpartum, though they may persist up to 4 weeks in some individuals. Confirm resolution of pruritus at the standard 6-week postpartum visit, and repeat bile acid and liver transaminase testing specifically in patients whose symptoms persist. Normalization of bile acids and transaminases postpartum does not itself rule out an underlying chronic liver disease — pursue further workup or specialist consultation for anyone with persistent symptoms, a persistent biochemical abnormality, or atypical features extending beyond the postpartum period.[1]
Recurrence in future pregnancies
Recurrence risk is approximately 70-90% — up to 90% where an underlying genetic predisposition is identified — though the risk may be somewhat lower if the index pregnancy was a multiple gestation, and can vary with gravidity and the interval since the index pregnancy. Discuss this risk with every affected patient at the postpartum visit, if it has not already been raised antenatally.[1]
Contraception
The World Health Organization endorses postpartum combined estrogen-progestin contraception as an acceptable option (Medical Eligibility Criteria) for patients with a history of ICP. However, counsel patients that they remain at risk of non-pregnant cholestasis with combined hormonal contraceptive use, and that this risk can be reduced by choosing a lower-estrogen-dose formulation. Combined hormonal contraceptives should be discontinued if symptoms of cholestasis develop while using them. Progestin-only contraception is associated with the lowest risk of non-pregnant cholestasis and is a reasonable preferred option where avoiding this risk is a priority.[1]
Long-term maternal risk
Individuals with a history of ICP are at increased long-term risk of cholecystitis, cholelithiasis, pancreatic disease, goiter, and hypothyroidism — plausibly related, at least in part, to the same underlying genetic predisposition in bile-acid handling that produced the ICP itself. Routine additional long-term hepatobiliary surveillance is not separately mandated, but keep this association in mind when a patient with a history of ICP later presents with biliary symptoms.[1]
Offspring outcomes
Infants born to a pregnancy affected by ICP have normal biopsychosocial development, but may carry an increased long-term risk of metabolic disease — altered lipid profiles and a higher body mass index have been reported by age 16 in some cohorts. This is a reasonable, low-pressure point to raise as part of general anticipatory guidance rather than a cause for additional testing in infancy.[1]
Monitoring & Follow-Up
Laboratory monitoring during pregnancy
Once ICP is diagnosed, monitor bile acid levels serially to track disease progression and identify the highest value reached — that peak value, not the most recent result, anchors both the fetal-monitoring plan and the delivery-timing decision (see Assessment & Diagnosis and Choose Initial Treatment). Individualize frequency to symptom severity and gestational age: every 2-4 weeks for early or mild disease, and every 1-2 weeks for more severe or later-gestation disease.[1]
Fetal surveillance
All patients should be advised to monitor fetal movements as the mainstay of surveillance. Formal antenatal fetal testing (cardiotocography, ultrasound) has not been shown to accurately predict which fetuses will suffer an adverse outcome and is not mandated — but where a unit has the resources and elects to offer risk-stratified monitoring, one reasonable approach ties monitoring frequency to the highest bile acid level:[1]
- Bile acids 40-99 µmol/L: obstetric ultrasound for biophysical profile, or electronic fetal heart rate monitoring, every 1-2 weeks.
- Bile acids 100 µmol/L or higher: obstetric ultrasound for biophysical profile, or electronic fetal heart rate monitoring, weekly or twice weekly; some units use daily inpatient electronic fetal heart rate monitoring for this group. There is currently no specific evidence that inpatient monitoring itself improves outcomes over outpatient monitoring — individualize the choice to patient risk factors, preference, and caregiver/unit resources.
Postpartum
Confirm resolution of pruritus at the 6-week postpartum visit and repeat bile acid and liver transaminase testing in anyone with persisting symptoms. Discuss future-pregnancy recurrence risk, and where the pregnancy was early-onset (before 32 weeks), consider referral for genetic evaluation (see Special Populations).[1]
Common Errors to Avoid
- Using a fasting bile acid level, or a non-pregnant reference range, to rule out ICP — non-fasting testing against the pregnancy-specific greater-than-19 µmol/L threshold is what current guidance recommends; a fasting or non-pregnant-range result can be falsely reassuring.
- Treating a single normal bile acid level as ruling out ICP in a patient with a genuinely suggestive presentation — pruritus can precede an abnormal bile acid level by 3-4 weeks; repeat testing in 2-4 weeks instead.
- Counselling patients that UDCA prevents stillbirth — the best available randomized evidence (PITCHES) did not show this, including in the severe subgroup; UDCA's evidence-supported benefits are symptom relief and a modest reduction in preterm birth risk.
- Anchoring delivery timing to the most recent bile acid level rather than the highest level recorded at any point in the pregnancy — a falling level on treatment does not reset the risk category.
- Prescribing dexamethasone, cholestyramine, phenobarbital, S-adenosylmethionine, activated charcoal, or epomediol to treat ICP — each has specifically been studied and shown ineffective.
- Ordering routine PT/PTT/INR or empirically starting vitamin K in every ICP patient — reserve this for patients with clinical evidence of a bleeding tendency.
- Attributing a primary skin rash or eruption to ICP — ICP produces itching without a primary lesion; a genuine rash points to an alternative pregnancy dermatosis and needs its own workup.
- Reassuring a patient that a normal cardiotocogram or ultrasound rules out subsequent fetal compromise — neither has been shown to reliably predict which ICP-affected fetus will decompensate; fetal movement monitoring remains the mainstay.
- Failing to raise the 70-90% future-pregnancy recurrence risk at the postpartum visit, or missing the referral opportunity for early-onset (before 32 weeks) disease, where a pathogenic ABCB11/ABCB4 variant is present in roughly 1 in 5 patients.
- Continuing combined hormonal contraception without counselling on the risk of non-pregnant cholestasis, or failing to advise stopping it if cholestatic symptoms recur outside pregnancy.
Clinical Decision Algorithm
Drug Tables
How to use this table: doses are adult obstetric doses for intrahepatic cholestasis of pregnancy specifically and require patient-specific confirmation. Drug pricing is intentionally omitted. Select any drug name to open its complete Pharmasist Drug Database page.
First-Line Pharmacotherapy — Ursodeoxycholic Acid
Recommended for severe ICP (bile acids ≥100 µmol/L) unless delivery is otherwise indicated; consider for non-severe ICP using shared decision-making.[1]
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Ursodiol (ursodeoxycholic acid) | 10-15 mg/kg/day PO in 2-3 divided doses; typical starting dose 500 mg PO every 12 hours; if pruritus is not relieved within 2 weeks, titrate every 1-2 weeks as needed to a maximum of 20 mg/kg/day | GI upset, diarrhea; generally well tolerated | Reduced absorption with aluminum-based antacids or cholestyramine — separate administration; may theoretically reduce oral contraceptive efficacy | Replaces roughly 60% of harmful (hydrophobic) bile salts. Randomized evidence (PITCHES) shows no reduction in total bile acids, perinatal death, preterm delivery, or NICU admission — real benefits are symptom relief and a modest reduction in preterm birth risk from pooled individual-participant data, not a proven stillbirth-prevention effect.[3] |
Symptomatic Pruritus Relief — Adjunctive, All Severities
Comfort measures alongside UDCA (or alone in mild disease); none affects bile acid levels or fetal risk.[1]
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Topical emollients | Applied liberally, as needed | Generally well tolerated; rare contact irritation | None significant | Simple, safe first-line comfort measure throughout pregnancy. |
| Hydroxyzine | 25-50 mg PO at bedtime | Sedation, dry mouth, dizziness, anticholinergic effects | Additive CNS depression with other sedating agents | Not specifically evaluated for efficacy in ICP; used as a comfort measure, particularly for nocturnal itch. |
Refractory Disease — Specialist-Directed Adjunct
For pruritus or bile acids that do not improve on UDCA alone; initiate only under specialist direction.[1]
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Rifampin (rifampicin) | 300-1200 mg/day, added to UDCA, per specialist protocol | Hepatotoxicity, GI upset, orange discoloration of body fluids | Potent CYP3A4/CYP2C9 inducer — reduces efficacy of numerous co-administered drugs, including oral contraceptives and many antimicrobials | A case series of 28 patients with severe, refractory ICP showed reduced bile acid levels with rifampin added to UDCA. Not a first-line agent — specialist-directed only. |
Vitamin K — Only With Demonstrated Deficiency
Not routine; reserve for a patient with clinical evidence of a bleeding tendency and a confirmed deficiency or coagulopathy with an abnormal PT.[1]
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Vitamin K1 (phytonadione) | 10 mg PO once daily | Generally well tolerated at oral doses | None significant at standard oral doses | Indicated only with demonstrated vitamin K deficiency and/or coagulopathy with an abnormal PT — most often from severe steatorrhea with fat-soluble vitamin malabsorption. Routine PT/PTT/INR testing and empiric supplementation are not recommended in typical ICP. |
Specifically ineffective for ICP — do not prescribe
| Drug | Dosage | Reason avoided | Drug interactions | Comments |
|---|---|---|---|---|
| Dexamethasone Avoid | N/A | Studied and shown ineffective for treating ICP | — | See the drug's own monograph for use in other indications (e.g., antenatal lung maturation), which is unrelated to this recommendation. |
| Cholestyramine Avoid | N/A | Studied and shown ineffective for treating ICP; historically associated with worsening fat-soluble vitamin malabsorption when used in this setting | — | Not routinely used in contemporary ICP practice. |
| Phenobarbital Avoid | N/A | Studied and shown ineffective for treating ICP | — | See the drug's own monograph for use in other indications (e.g., seizure disorders), which is unrelated to this recommendation. |
| S-adenosylmethionine (SAMe) Avoid | N/A | Studied and shown ineffective for treating ICP | — | An over-the-counter supplement sometimes self-initiated by patients — actively ask about use. |
| Activated charcoal Avoid | N/A | Studied and shown ineffective for treating ICP | — | Not the same use case as charcoal for acute poison management. |
| Epomediol Avoid | N/A | Studied and shown ineffective for treating ICP | — | Not widely available in Canada; included for completeness. |
Evidence note: drug inventory, dosing, adverse effects, and comments reflect the current SOGC guideline, cross-checked against the primary trial and meta-analysis evidence it is based on.[1][2]
References
- Guideline No. 452: Diagnosis and Management of Intrahepatic Cholestasis of Pregnancy — Journal of Obstetrics and Gynaecology Canada, Society of Obstetricians and Gynaecologists of Canada (Hobson SR, Cohen ER, Gandhi S, Jain V, Niles KM, Roy-Lacroix ME, Wo BL). J Obstet Gynaecol Can 2024;46(8):102618
- Association of adverse perinatal outcomes of intrahepatic cholestasis of pregnancy with biochemical markers: results of aggregate and individual patient data meta-analyses — The Lancet (Ovadia C, Seed PT, Sklavounos A, et al.). Lancet 2019;393(10174):899-909
- Ursodeoxycholic acid versus placebo in women with intrahepatic cholestasis of pregnancy (PITCHES): a randomised controlled trial — The Lancet (Chappell LC, Bell JL, Smith A, et al.). Lancet 2019;394(10201):849-860
Professional reference only. Apply clinical judgment and verify patient-specific decisions against current authoritative guidance and product information.